SRNE (SRNE) Stock Price & Analysis
SRNE (SRNE) rose 0.00% to USD 0 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
SRNE last closed at USD 0; the session ranged USD 0.01–0.01 on volume of 501,682 shares. Market capitalization is $330,768, with a 52-week range of USD 0–0.07 (PNK). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0 – 0.07 |
| Volume | 501,682 shares |
| Market Cap | $330,768 |
| Exchange | PNK |
Technical Analysis (SRNE)
Nexqual's technical model rates SRNE "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 42.07 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (SRNE)
Wall Street analysts rate SRNE "None", per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | None |
|---|
Earnings (SRNE)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-03-31 | USD -0.26 vs est -0.16 ▼ miss |
| 2022-12-31 | USD -0.49 vs est -0.15 ▼ miss |
| 2022-09-30 | USD -0.2 vs est -0.26 ▲ beat |
| 2022-06-30 | USD -0.54 vs est -0.2 ▼ miss |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (SRNE)
| Total Revenue | $64.27M |
|---|---|
| Revenue Growth (YoY) | +31.10% |
| Gross Margin | -245.01% |
| Operating Margin | -510.93% |
| Profit Margin | +0.00% |
| Current Ratio | 0.41 |
| Total Cash | $80.64M |
| Total Debt | $207.60M |
| Free Cash Flow | $-57.53M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (SRNE)
Nexqual rates SRNE's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $81M cash vs $208M debt |
| Cash Flow | Weak — FCF negative: -$58M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SRNE)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 551.28M |
| Float | 539.11M |
| Short % of Float | +11.96% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (SRNE)
SRNE is led by Henry H. Ji (age 61), Chairman, President & CEO, per Nexqual as of September 8, 2026 at 05:44 UTC.
| Chairman, President & CEO | Henry H. Ji (age 61) |
|---|---|
| Chief Technology Officer | Scott Schaus |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 2.04% |
| INO | Inovio Pharmaceuticals, Inc. | USD 1.43 | ▲ 5.15% |
| IBIO | iBio, Inc. | USD 1.31 | ▲ 0% |
| NVAX | Novavax, Inc. | USD 10.22 | ▼ 0.97% |
| CODX | Co-Diagnostics, Inc. | USD 1.16 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.